SG Americas Securities LLC Buys 5,042 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)

SG Americas Securities LLC lifted its stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 35.1% in the 4th quarter, Holdings Channel reports. The institutional investor owned 19,391 shares of the company’s stock after acquiring an additional 5,042 shares during the period. SG Americas Securities LLC’s holdings in Larimar Therapeutics were worth $75,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the business. Janus Henderson Group PLC raised its position in Larimar Therapeutics by 27.2% in the third quarter. Janus Henderson Group PLC now owns 5,566,855 shares of the company’s stock worth $36,379,000 after purchasing an additional 1,189,467 shares in the last quarter. Sphera Funds Management LTD. raised its position in Larimar Therapeutics by 32.6% in the third quarter. Sphera Funds Management LTD. now owns 414,478 shares of the company’s stock worth $2,715,000 after purchasing an additional 102,009 shares in the last quarter. Jane Street Group LLC raised its position in Larimar Therapeutics by 80.1% in the third quarter. Jane Street Group LLC now owns 113,783 shares of the company’s stock worth $745,000 after purchasing an additional 50,622 shares in the last quarter. GSA Capital Partners LLP raised its position in Larimar Therapeutics by 108.9% in the third quarter. GSA Capital Partners LLP now owns 107,408 shares of the company’s stock worth $704,000 after purchasing an additional 55,984 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Larimar Therapeutics by 152.5% during the third quarter. Wellington Management Group LLP now owns 105,246 shares of the company’s stock worth $689,000 after buying an additional 63,563 shares in the last quarter. Institutional investors and hedge funds own 91.92% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on LRMR shares. Truist Financial started coverage on shares of Larimar Therapeutics in a report on Wednesday, January 29th. They set a “buy” rating and a $18.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Larimar Therapeutics in a research note on Friday, January 24th. Finally, William Blair reissued an “outperform” rating on shares of Larimar Therapeutics in a research note on Tuesday, November 19th. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $20.13.

Larimar Therapeutics Price Performance

LRMR opened at $3.27 on Friday. Larimar Therapeutics, Inc. has a one year low of $3.01 and a one year high of $13.68. The stock has a market capitalization of $208.66 million, a P/E ratio of -2.84 and a beta of 0.91. The company’s 50 day simple moving average is $4.10 and its 200-day simple moving average is $6.24.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.